|  |  | 

India Top Headlines

First batch of DRDO’s anti-Covid drug to launch on Monday | India News


NEW DELHI: The first batch of anti-COVID 2-DG drug, developed by the DRDO, will be released on Monday by Defense Minister Rajnath Singh and Health Minister Harsh Vardhan, authorities said.
The Comptroller General of Drugs of India (DGCI) approved the oral drug for emergency use as a complementary therapy in patients with moderate to severe coronavirus, the Defense Ministry said earlier this month.
Officials said the first batch of the drug will be delivered by the two ministers at an event at the Defense Research and Development Organization (DRDO) headquarters here.
The ministry on May 8 said that clinical trials of the drug, 2-deoxy-D-glucose (2-DG), showed that it helps in faster recovery of hospitalized patients and reduces dependence on supplemental oxygen.
The drug’s approval came at a time when India is dealing with a record wave of the coronavirus pandemic that has pushed the country’s healthcare infrastructure to the limit.
“In the second wave of COVID-19 underway, a large number of patients are facing severe oxygen dependence and need hospitalization. The drug is expected to save precious lives due to the mechanism of its operation on infected cells. This also reduces the hospital stay of COVID-19 patients, “the ministry had said.
The drug’s anti-COVID therapeutic application has been developed by the Institute of Nuclear Medicine and Allied Sciences (INMAS), a leading laboratory of DRDO, in collaboration with Dr Reddy’s Laboratories (DRL) in Hyderabad.
The drug comes as a powder in a sachet and is taken by mouth by dissolving it in water, the ministry said.
In efficacy trends, he said, patients treated with 2-DG showed faster symptomatic cure than standard of care (SoC) on several endpoints.

Times of India